The Patel Chem Specialities IPO will open on July 25, 2025, and close on July 29, 2025. It is a Book Built Issue through which the company plans to raise approximately ₹58.80 crores. This includes a fresh issue worth ₹58.80 crores, along with an offer for sale of up to [.] equity shares having a face value of ₹10 each.

The IPO price band is set between ₹82 and ₹84 per share. The quota allocation is 35% for retail investors, 50% for Qualified Institutional Buyers (QIB), and 15% for High Net-worth Individuals (HNI). The shares are scheduled to be listed on the BSE on August 1, 2025, with the allotment expected to be finalized on July 30, 2025.

Financially, the company recorded a revenue of ₹105.55 crores in 2025, up from ₹82.72 crores in 2024. Net profit also rose to ₹10.57 crores in 2025 compared to ₹7.66 crores in 2024. Based on its financial performance, the IPO appears to be a promising option for long-term investors

About Patel Chem Specialities IPO

Patel Chem Specialties Limited is a trusted leader in the manufacturing of high-quality pharmaceutical excipients - raw material for drug formulation. With decades of experience, we specialize in producing a wide range of excipients, including Sodium Carboxy Methyl Cellulose (Sodium CMC), Sodium Starch Glycolate (SSG), Croscarmellose sodium (CCS), Calcium CMC, Magnesium stearate andpregelatinised starch and also producing key API intermediate Sodium Monochloroacetate.
Founded on the principles of quality, innovation, and customer-centricity, we are committed to supporting the pharmaceutical industry with reliable, safe, and efficient excipient solutions.
At Patel Chem Specialties, we believe in fostering strong relationships with our clients, providing tailored solutions that meet their specific needs. Our dedicated team of experts continuously strives to improve our offerings through research and development, ensuring that we remain at the forefront of the pharmaceutical excipient industry.